Health and Healthcare
Gilead Wins CV Therapeutics Bid; Higher Bid Coming? (GILD, CVTX)
Published:
Last Updated:
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.
This deal is via a tender offer and second step merger. The board has agreed to recommend to its stockholders to tender their shares. This is interesting because CV’s board had fought off a $16.00 buyout from Astellas.
The transaction is valued at approximately $1.4 billion. Gilead believes it will be dilutive to 2009 earnings, will be neutral or accretive to 2010 earnings, and will be accretive to earnings in 2011 and beyond.
CV Therapeutics focuses on the development of small molecule drugs for the treatment of cardiovascular diseases. In 2008, its Ranexa and Lexiscan contributed to total revenue of $154.5 million. It also has a pipeline which includes multiple product candidates in evaluation stages for the treatment of atrial fibrillation, pulmonary diseases and diabetes.
The tender is subject to to a majority tender of holders and to regulatory approval. These should go through. Where this gets really interesting is that the stock is trading up at $20.40 in pre-market trading. Some are wondering if Astellas will come knocking on the door again.
JON C. OGG
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
